Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T68816
|
||||
Former ID |
TTDI01780
|
||||
Target Name |
VEGF receptor
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Age related macular degeneration [ICD9: 362.5; ICD10: H35.3] | ||||
Angina pectoris [ICD9: 413; ICD10: I20] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Diabetic macular edema [ICD9: 250, 362.01, 362.07, 362.53, 782.3; ICD10: E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9] | |||||
Diabetic retinopathy [ICD9: 250.5; ICD10: H36, E10.3, E11.3, E13.3] | |||||
Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10: E11.40] | |||||
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
BioChemical Class |
Kinase
|
||||
EC Number |
EC 2.7.10.1
|
||||
Drugs and Mode of Action | |||||
Drug(s) | KH-902 | Drug Info | Phase 3 | Diabetic macular edema | [523629] |
ASP-8477 | Drug Info | Phase 2 | Neuropathic pain | [524649] | |
BFH-772 | Drug Info | Phase 2 | Psoriasis | [523654] | |
XL-820 | Drug Info | Phase 2 | Solid tumours | [522178] | |
AG-013958 | Drug Info | Phase 1/2 | Age related macular degeneration | [521610] | |
VEGF-2 gene therapy | Drug Info | Phase 1 | Diabetic neuropathy | [534594] | |
HuMV833 | Drug Info | Discontinued in Phase 1 | Cancer | [547036] | |
AZD-9935 | Drug Info | Terminated | Solid tumours | [547683] | |
Genevx | Drug Info | Terminated | Angina pectoris | [547116] | |
RG-8803 | Drug Info | Terminated | Diabetic retinopathy | [546922] | |
ZD-4190 | Drug Info | Terminated | Solid tumours | [546662] | |
Inhibitor | AG-013958 | Drug Info | [544034] | ||
RG-8803 | Drug Info | [551906] | |||
XL-820 | Drug Info | [550402] | |||
Modulator | ASP-8477 | Drug Info | [524649] | ||
Genevx | Drug Info | [549790] | |||
KH-902 | Drug Info | [531802] | |||
VEGF-2 gene therapy | Drug Info | [534161] | |||
ZD-4190 | Drug Info | [525712] | |||
Antagonist | AZD-9935 | Drug Info | [550140] | ||
Agonist | BFH-772 | Drug Info | [550850] | ||
Pathways | |||||
References | |||||
Ref 521610 | ClinicalTrials.gov (NCT00090532) A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration. U.S. National Institutes of Health. | ||||
Ref 522178 | ClinicalTrials.gov (NCT00570635) A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib. U.S. National Institutes of Health. | ||||
Ref 523629 | ClinicalTrials.gov (NCT01436864) A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD. U.S. National Institutes of Health. | ||||
Ref 523654 | ClinicalTrials.gov (NCT01449591) Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. U.S. National Institutes of Health. | ||||
Ref 524649 | ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health. | ||||
Ref 534594 | Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998 Mar 31;97(12):1114-23. | ||||
Ref 546662 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009540) | ||||
Ref 546922 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011158) | ||||
Ref 547036 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012394) | ||||
Ref 524649 | ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health. | ||||
Ref 525712 | ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000 Feb 15;60(4):970-5. | ||||
Ref 526435 | Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93. | ||||
Ref 531802 | Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53. | ||||
Ref 534161 | Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996 Aug 10;348(9024):370-4. | ||||
Ref 544034 | Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.